Aurobindo Pharma achieved robust results during the
year 1998-99. The sales recorded an increase of 86 % over
the sales of 1997-98. The company could achieve this higher
growth by increasing the capacities for semi - synthetic
pencillins, quinolones, etc. and also by introducing
both sterile and non- sterile cephalosporins to
its product mix. Presently exports constitute about 40%
of the total turnover. The wholly owned subsidiary company
at Miami in US has commenced operations. It has
also set up a wholly owned subsidiary in Hong Kong
and a jont venture in Thailand.
The company is focussing its thrust on formulations. Majority
of the future investments would be in this direction.Plans
are on to launch new products to increase the therapeutic
range. In the next two years they plan to invest Rs. 60
crore and if it materialises it will soon be in a different
Automation, computerisation, information technology,
virtual offices will become common place. Electronic Commerce,
robots in production, will offer workers free time and
a healthy environment, ensuring high level of productivity.
Through reverse engineering and massive production capabilities
in semi-synthetic pencillins,Aurobindo has become a top
player in the country and the world's 5th largest producer
of semi-synthetic pencillins. Aurobindo today has the
capacity of producing Asia's largest Sterile cephalosporins.
Public listing of the company's stock through the bought
out deal mechanism is a major landmark in the history
of Aurobindo. The company has issued bonus shares twice
in the last five years.The top Management and the Board
of Directors are always on the move for new innovations.
Sincere commitment, a strong will, perseverance, coupled
with careful planning have been the pillars on which the
success of Aurobindo has been achieved. Understanding
of the market, updating technology for cost effectiveness
and innovation have helped them succeed. The company hopes
to achieve a sales target of Rs. 1000 crores by 2001 A.D.